Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06613633
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-09-23
Brief Title:
Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Pattern of Failure and Feasibility of Consolidative Stereotactic Radiotherapy in Third-generation EGFR-TKI-treated Metastatic EGFR-mutant Non-small Cell Lung Cancer A Prospective Observational Study
Status:
COMPLETED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this observational study is to explore the feasibility of stereotactic radiotherapy SRT as consolidation therapy for patients with advanced non-small-cell lung cancer who were treated with third-generation epidermal growth factor receptor-tyrosine kinase inhibitor EGFR-TKI The investigators plan to explore the time to achieve the best response after EGFR-TKI treatment the characteristics of the distribution of lesions when the best response is achieved the feasibility of SRT when the best response is achieved and the phenotype of disease progression after EGFR-TKI resistance
In summary this study will provide critical information for exploring the feasibility and optimal design of SRT as consolidation therapy for advanced NSCLC patients treated with third-generation EGFR-TKI which will further promote the optimization of comprehensive treatment for EGFR-mutant advanced NSCLC
In summary this study will provide critical information for exploring the feasibility and optimal design of SRT as consolidation therapy for advanced NSCLC patients treated with third-generation EGFR-TKI which will further promote the optimization of comprehensive treatment for EGFR-mutant advanced NSCLC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None